Alnylam and Tenaya Therapeutics entered a research collaboration in which Tenaya will deliver up to 15 novel genetic targets for cardiovascular disease; Alnylam paid $10 million up front and the agreement includes up to $1.13 billion in potential development, regulatory and commercial milestones. Tenaya will continue advancing its internal gene‑therapy programs while the collaboration uses Tenaya’s discovery engine to nominate targets for RNAi discovery. The pact marks a major pharma‑biotech pairing in cardiovascular genetics, combining Tenaya’s cardiac target platform with Alnylam’s RNAi development and commercialization capabilities. Financial terms reflect the high strategic value placed on human‑genetics‑led target pipelines in cardio R&D. If targets advance to clinical candidates and reach approval, the collaboration could reshape therapeutic options for heart disease and validate Tenaya’s platform as a source of first‑in‑class cardiovascular biology.